Target intelligence / Profile preview

Insulin-like growth factor-binding protein complex acid-labile subunit (IGFALS)

Target
IGFALS
Molecular classification
Glycoprotein, Leucine-rich repeat protein, Carrier protein, Other
01

Overview

The insulin-like growth factor-binding protein complex acid-labile subunit (IGFALS), commonly referred to as the acid-labile subunit (ALS), is a liver-secreted glycoprotein belonging to the leucine-rich repeat superfamily. It plays a critical role in the endocrine insulin-like growth factor (IGF) system by forming a high-molecular-weight ternary complex of approximately 150 kDa with IGF-1 or IGF-2 and insulin-like growth factor-binding protein-3 (IGFBP-3) or IGFBP-5. This ternary complex restricts the passage of IGFs through the vascular endothelium, thereby extending their circulating half-life and regulating their bioavailability to target tissues. Mutations in the IGFALS gene lead to primary acid-labile subunit deficiency (ACLSD), a rare autosomal recessive disorder characterized by severe reductions in circulating IGF-1 and IGFBP-3, moderate postnatal growth retardation, delayed puberty, and insulin resistance.

While there are currently no approved drugs that directly target IGFALS, its expression is highly regulated by growth hormone (GH). Recombinant human growth hormone (somatropin) indirectly increases IGFALS levels, whereas the GH receptor antagonist pegvisomant decreases them. Additionally, recombinant human IGF-1 (mecasermin) is utilized in clinical management, though patients with complete ALS deficiency show a poor response due to their inability to form the stabilizing ternary complex. Emerging therapeutic strategies, such as RNA interference (RNAi) agents targeting IGFALS, are being explored for the treatment of IGF-driven disorders like acromegaly and certain cancers.

Other names
Acid-labile subunitALSInsulin-like growth factor-binding protein complex acid labile subunitIGFALSIBPALS
02

Mechanism of action

Indirect modulation of expression via growth hormone receptor signaling, and ternary complex formation with recombinant IGF-1 and IGFBP-3

03

Biological functions

Regulation of insulin-like growth factor transport and uptakeProtein-protein interactionCell adhesionGrowth and developmentOther
04

Disease associations

Acid-labile subunit deficiencyShort statureGrowth retardationInsulin resistancePreeclampsiaCancerOther
05

Safety considerations

HypoglycemiaInsulin resistanceGrowth failureAltered bone densityPotential risk of tumor progression or type 2 diabetes with long-term dysregulation
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

Serum IGFALS levelsSerum IGF-1 levelsSerum IGFBP-3 levelsIGFALS gene mutations

Beyond the preview

Go deeper on Insulin-like growth factor-binding protein complex acid-labile subunit (IGFALS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Insulin-like growth factor-binding protein complex acid-labile subunit (IGFALS).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call